Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam R Glassman

Showing results (11-20 of 127) with videos related to

Pageof 13
Sort By:
JAMA Ophthalmology|April 22, 2016
Panretinal Photocoagulation vs Anti-Vascular Endothelial Growth Factor for Proliferative Diabetic Retinopathy-ReplyJeffrey G Gross, Adam R Glassman
JAMA Ophthalmology|October 16, 2025
Benefits and Limitations of Using Population Databases for Eye Research-More Than Meets the EyeDolly Ann Padovani-Claudio, Adam R Glassman
The New England Journal of Medicine|April 23, 2020
Evaluation and Care of Patients with Diabetic RetinopathyLee M Jampol, Adam R Glassman, Jennifer Sun
JAMA Ophthalmology|February 3, 2017
Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema-ReplyNeil M Bressler, Adam R Glassman, David W Hutton
Ophthalmology|November 22, 2017
ReplySusan B Bressler, Wesley T Beaulieu, Adam R Glassman
JAMA|May 23, 2023
Four-Year Visual Outcomes After Intravitreous Aflibercept for Vision-Threatening Complications of Diabetic Retinopathy-ReplyJennifer K Sun, Adam R Glassman, Raj K Maturi, et al.
The New England Journal of Medicine|July 30, 2015
Targeting the Effect of VEGF in Diabetic Macular EdemaJohn A Wells, Adam R Glassman, Lee M Jampol
JAMA Ophthalmology|March 3, 2022
Spotlight on the DRCR Retina Network's Photobiomodulation for Diabetic Macular Edema TrialJennifer K Sun, Adam R Glassman, Lee M Jampol
American Journal of Ophthalmology|September 4, 2007
The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trialsAbdhish R Bhavsar, Michael S Ip, Adam R Glassman, et al.
The New England Journal of Medicine|July 30, 2020
Evaluation and Care of Patients with Diabetic Retinopathy. ReplyLee M Jampol, Adam R Glassman, Jennifer K Sun
Pageof 13

Showing results (11-20 of 127) with videos related to

Sort By:
Pageof 13
JAMA Ophthalmology|April 22, 2016
Panretinal Photocoagulation vs Anti-Vascular Endothelial Growth Factor for Proliferative Diabetic Retinopathy-ReplyJeffrey G Gross, Adam R Glassman
JAMA Ophthalmology|October 16, 2025
Benefits and Limitations of Using Population Databases for Eye Research-More Than Meets the EyeDolly Ann Padovani-Claudio, Adam R Glassman
The New England Journal of Medicine|April 23, 2020
Evaluation and Care of Patients with Diabetic RetinopathyLee M Jampol, Adam R Glassman, Jennifer Sun
JAMA Ophthalmology|February 3, 2017
Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema-ReplyNeil M Bressler, Adam R Glassman, David W Hutton
Ophthalmology|November 22, 2017
ReplySusan B Bressler, Wesley T Beaulieu, Adam R Glassman
JAMA|May 23, 2023
Four-Year Visual Outcomes After Intravitreous Aflibercept for Vision-Threatening Complications of Diabetic Retinopathy-ReplyJennifer K Sun, Adam R Glassman, Raj K Maturi, et al.
The New England Journal of Medicine|July 30, 2015
Targeting the Effect of VEGF in Diabetic Macular EdemaJohn A Wells, Adam R Glassman, Lee M Jampol
JAMA Ophthalmology|March 3, 2022
Spotlight on the DRCR Retina Network's Photobiomodulation for Diabetic Macular Edema TrialJennifer K Sun, Adam R Glassman, Lee M Jampol
American Journal of Ophthalmology|September 4, 2007
The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trialsAbdhish R Bhavsar, Michael S Ip, Adam R Glassman, et al.
The New England Journal of Medicine|July 30, 2020
Evaluation and Care of Patients with Diabetic Retinopathy. ReplyLee M Jampol, Adam R Glassman, Jennifer K Sun
Pageof 13